No Data
No Data
Nikkei average contribution ranking (pre-opening) ~ Nikkei average rebounds, with Advantest pushing up about 44 yen per share.
At the end of the session 30 days ago, the number of advancing stocks in the Nikkei Average constituent stocks was 138, the number of declining stocks was 85, and the number of unchanged stocks was 2. The Nikkei Average rebounded. It finished the morning session trading at ¥38,585.43 (approximate volume of 700,000,000 shares), up ¥222.90 (+0.58%) from the previous day. The U.S. stock market on the 29th was mixed. The Dow Jones Average rose 243.63 points (+0.59%) to 41,335.05, while the Nasdaq declined 39.60 points (-0.23%) to 17,516.
Three points to watch in the afternoon session ~ rebound but temporary halt at the 75-day moving average.
In the afternoon of the 30th, the following 3 points are worth noting in the trading: - The Nikkei Average rebounded, but paused at the 75-day moving average - The dollar-yen is firm, hovering around 144 yen - The top contributors to the price increase are Advantest <6857> and Softbank Group <9984>. The Nikkei Average rebounded, but paused at the 75-day moving average. It rebounded with an increase of 222.90 yen (+0.58%) to 38,585.43 yen (with a trading volume of approximately 710 million shares) at the end of the morning session.
The Nikkei average rebounded, but it paused its rise at the 75-day moving average.
The Nikkei Average rebounded. At the end of the morning session, it closed at 38,585.43 yen (+0.58%, up 222.90 yen from the previous day) with an approximate volume of 70.10 million shares. The U.S. stock market on the 29th was mixed. The Dow Jones Industrial Average closed at 41,335.05 (+0.59%, up 243.63 dollars), the Nasdaq closed at 17,516.43 (-0.23%, down 39.60 points), and the S&P500 closed at a decrease of 0.22 points (-0.004%). The domestic gross domestic product (GDP) for the April-June quarter.
SNBL Partners With Astellas Pharma in Drug Discovery
Japanese Shares Flat as Nvidia's Earnings Fail to Boost Sentiment
Astellas' Padcev Combo Approved by EU for Advanced Urothelial Cancer
No Data